Boehringer Ingelheim and Sino Biopharmaceutical Enter into an Option and License Agreement Worth Over $7B to Advance Next-Gen Cancer Therapies

Shots: Boehringer Ingelheim & Sino Biopharmaceutical (SBP Group) have entered into a strategic multi-program option & license agreement to advance next-gen cancer therapies based on ADC & T-cell engager (TcE) technologies SBP Group will receive $358M in upfront & near-term payments and is eligible for ~$7B in option-exercise, development, regulatory & commercial milestones, plus up to double-digit tiered royalties The deal covers 6 preclinical biologic programs (5 from LaNova Medicines, 1 from Beijing Tide); SBP will lead early development, after which BI may opt for exclusive ex-China rights to 4 programs & global rights to 2 Ref: GlobeNewswire  |   Image: Boehringer Ingelheim  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Boehringer Ingelheim and Sino Biopharmaceutical Enter into an Option and License Agreement Worth Over $7B to Advance Next-Gen Cancer Therapies appeared first on PharmaShots.